AstraZeneca's $1.5B AI Drug Deal with Insitro
AstraZeneca is paying $40 million upfront and up to $1.46 billion in milestones for insitro's AI drug discovery platform. Alex and Jordan explain the science and the stakes.
Speaker 1: AstraZeneca just made one of the year's biggest bets on
artificial intelligence in drug discovery.
Speaker 2: Tell us about the deal.
Speaker 1: The British drugmaker announced Thursday a worldwide exclusive collaboration with In-Citro,
a California-based AI biotech company. The goal is to discover
and develop new treatments for two hard-to-treat conditions, a severe
liver disease called MASH, and cardiomyopathies, a group of diseases
that affect the heart muscle.
Speaker 2: What are the financial terms?
Speaker 1: AstraZeneca will pay $ 40 million up front. then Insitro is
eligible for up to about $ 1. 46 billion in potential development
and commercial milestone payments, plus a single-digit percentage of future
sales and royalties. So the total package could reach roughly $ 1. 5 billion.
Speaker 2: What does Insitro actually bring to the table?
Speaker 1: It's a virtual human AI platform. It combines lab-grown cell
models with machine learning to figure out the actual biological
drivers of disease. The idea is to find the root causes,
not just the symptoms. and to advance AstraZeneca's chosen targets
from early discovery to the development candidate stage. Then AstraZeneca
takes over, runs and funds the clinical trials, handles the regulators,
and sells the medicines.
Speaker 2: Why are these two diseases so hard to treat?
Speaker 1: Because they're what scientists call heterogeneous. Patients with the same
diagnosis can have very different biology underneath, so one treatment
rarely works for everyone. Historically, researchers have struggled to pinpoint
the root biological drivers— which is exactly where AI might help.
As one AstraZeneca executive put it, choosing the right targets
for the discovery pipeline is one of the hardest things
the company does.
Speaker 2: Is InCitro working with other big pharma companies too?
Speaker 1: Yes, and that's part of the story. InCitro recently expanded
its partnership with Bristol-Myers Squibb on ALS, that's Lou Gehrig's disease,
and it teamed up with Eli Lilly to build AI
models that predict how small molecules behave in living organisms.
AstraZeneca is joining a crowded dance floor.
Speaker 2: How did the market react?
Speaker 1: AstraZeneca shares were up about 2.2% in pre-market trading on Thursday.
Investors like AI drug discovery deals because finding better targets
earlier could save billions in failed clinical trials down the road.
Speaker 2: But we should be honest about the timeline here, right?
No drugs are coming next year.
Speaker 1: Exactly. No drug candidates have been named, and this program
is at a very early discovery stage. The money is
mostly backloaded, tied to milestones that may be years away.
This is a bet that AI can crack diseases that
have resisted decades of traditional research.
Speaker 2: It's still a sign of where pharma is heading.
Speaker 1: Absolutely. Big drug companies are leaning harder and harder on
AI to do the hardest part of their job, deciding
what to research in the first place. If InCitro's virtual
human platform can find causal biology that humans missed, that's
worth far more than $ 1. 5 billion. We'll be watching to
see if the science delivers.
Speaker 2: Let's zoom out for a second. Why is everyone in
pharma suddenly obsessed with AI target discovery?
Speaker 1: Because the old model is brutally expensive. It can take
more than a decade and billions of dollars to bring
a drug to market. And most candidates fail in clinical
trials because the biological target was wrong from the start.
If AI can pick better targets on day one, you
fail less, spend less, and get to patients faster. That's
the promise anyway.
Speaker 2: And MASH in particular is a huge market opportunity, right?
Speaker 1: Enormous mash is a severe form of fatty liver disease
that can lead to scarring and liver failure and it's
tied to the global rise in obesity and metabolic disease
there are very few effective treatments whoever cracks it first
is looking at a multi-billion dollar market same story with
cardiomyopathies where patients desperately need options beyond managing symptoms